Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11946933 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL19002176 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL14556074 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL12038672 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL16406411 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL17190802 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL14556018 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL13478686 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL14556014 | 1.00 | THRB (0.38) | THRBLMNA | |
| SCHEMBL11953924 | 1.00 | THRB (0.38) | THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028629-A1 | IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF | OBI PHARMA, INC. (TW) | 2018-02-01 | — | — | US | disclosed |
| US-20180028629-A1 | IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF | OBI PHARMA, INC. (TW) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028629-A1 | IMMUNOGENIC/THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF | OGA, FUT4, B3GAT3 | THRB 499/4885LMNA 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.